focus -WSS

focus

author：knowledge 2025-09-27 13:04:17 - browse：5

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： SCOTUS questions limit to govt efforts to fight misinformation

knowledge

Wikipedia

hotspot

WSS

Nurses recount patients attacks

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Pfizer is about to make a big push in cancer. Will investors listen?

Gene editing the human germline: What are the risks?

Leading voice in opioid treatment defends methadone clinic system

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

leisure time

focus

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Neuroscience’s long legacy of racism

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Bluebird, CVS, Contineum

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Wildfire smoke exposes gaps in outdoor worker protections

5 ways to address the shortage of health care workers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Doctor of U.S. President Joe Biden says he is fit for duty

focus

CDC advisory group OKs chikungunya vaccine

STAT Madness 2024: Meet the contenders

Creating egg and sperm cells from stem cells raises ethical issues

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Color Health wants to make cancer screenings convenient

Cholera vaccine supplies dangerously low, outbreaks surging

knowledge

Wikipedia

hotspot

leisure time